trial

A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion

NCTId NCT06372210
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 54 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2023-07-19
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
54 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2023-06-26
Primary completion
2023-07-19
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
AripiprazoleD-Tect Patch

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

1 total
Garden Grove, United States

Facts & assertions

4 sourced
Enrollment
54
Phase
NA
Primary Completion Date
2023-07-19
Status
COMPLETED
relationships
The graph out of here
drug
Aripiprazole
drug
D-Tect Patch
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Major Depressive Disorder
indication
Mental Disorder
indication
Depressive Disorder, Major
indication